Glaxo to take full control of Cellzome
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Glaxo, which currently owns just under one fifth of Cambridge-based Cellzome, is paying £61m in cash to buy up the rest of the company, which will become part of Glaxo's research and development (R&D) organisation.
Cellzome's proteomics technologies can be used throughout the drug discovery process from screening to selectivity profiling of compounds in different cells and also in patient samples.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists the opportunity to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.
Glaxo and Cellzome have two active early stage research collaborations using these discovery capabilities within the immune-inflammation therapy area.
Simultaneous with the acquisition, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which would hold the rights to certain of Cellzome's assets and activities that Glaxo does not want as part of its drugs development pipeline.
JH
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
US election – is the Trump Trade back?
The US election is around the corner. How does Trump influence US markets?
By Alex Rankine Published
-
James Halstead drives profits: should you buy?
James Halstead will rebound from a weak patch, while tax changes would be a buying opportunity
By Jamie Ward Published